Demonstrates how platinum nanozymes accelerate wound healing in diabetic models, suggesting a new therapeutic approach.
Purpose: This study aims to develop a therapeutic agent that accelerates the healing of chronic diabetic wounds by harnessing the highly efficient enzyme-mimicking activity of platinum nanozymes, and to elucidate its underlying mechanisms, thereby offering new insights for the treatment of diabetic wounds. Methods: SHA-PtNPs were synthesized using sodium hyaluronate (SHA) as the carrier, and their structural features were characterized by XRD, TEM, XPS and FTIR. The composite was then applied to evaluate wound-healing efficacy in diabetic mice. Furthermore, H&E staining, immunofluorescence staining, and other analyses were employed to investigate its underlying mechanisms in promoting wound repair. Results: The results revealed that SHA-PtNPs significantly accelerated wound closure through multiple mechanisms: (1) effective suppression of inflammatory responses and related cytokine production; (2) promotion of TGF-β 1 secretion and upregulation of CD31 and α-SMA expression, thereby enhancing angiogenesis and tissue contraction; and (3) induction of macrophage polarization from the pro-inflammatory M1 phenotype to the pro-healing M2 phenotype. Conclusion: These findings suggest that SHA-PtNPs, as a nanozyme-based material, hold great potential as an efficient therapeutic agent for diabetic wound healing, demonstrating a synergistic mechanism that integrates ROS regulation with immune microenvironment modulation.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: